Aveanna Healthcare (NASDAQ:AVAH) Stock Rating Lowered by Wall Street Zen

Aveanna Healthcare (NASDAQ:AVAHGet Free Report) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a note issued to investors on Friday.

A number of other equities research analysts have also recently weighed in on AVAH. Truist Financial cut their price objective on shares of Aveanna Healthcare from $6.00 to $5.50 and set a “hold” rating on the stock in a research note on Friday, April 11th. UBS Group lifted their price objective on shares of Aveanna Healthcare from $4.50 to $5.00 and gave the company a “sell” rating in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $5.13.

View Our Latest Research Report on Aveanna Healthcare

Aveanna Healthcare Price Performance

NASDAQ AVAH opened at $5.02 on Friday. Aveanna Healthcare has a 12 month low of $2.47 and a 12 month high of $6.19. The company has a 50-day moving average of $5.13 and a 200-day moving average of $4.87. The company has a market cap of $979.35 million, a P/E ratio of 251.00 and a beta of 2.03.

Insiders Place Their Bets

In other Aveanna Healthcare news, CAO Deborah Stewart sold 15,457 shares of the business’s stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $5.56, for a total value of $85,940.92. Following the sale, the chief accounting officer now directly owns 285,396 shares in the company, valued at approximately $1,586,801.76. The trade was a 5.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Patrick A. Cunningham sold 18,500 shares of the business’s stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $4.93, for a total transaction of $91,205.00. Following the completion of the sale, the insider now owns 327,869 shares in the company, valued at approximately $1,616,394.17. This trade represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 7,120,925 shares of company stock worth $37,869,472. 7.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Aveanna Healthcare

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Banque Transatlantique SA purchased a new position in Aveanna Healthcare in the 1st quarter worth about $25,000. KLP Kapitalforvaltning AS purchased a new position in Aveanna Healthcare in the 4th quarter worth about $35,000. BNP Paribas Financial Markets purchased a new position in Aveanna Healthcare in the 4th quarter worth about $35,000. Tower Research Capital LLC TRC increased its stake in Aveanna Healthcare by 662.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,889 shares of the company’s stock worth $36,000 after purchasing an additional 6,854 shares in the last quarter. Finally, Catalyst Funds Management Pty Ltd increased its stake in Aveanna Healthcare by 321.4% in the 4th quarter. Catalyst Funds Management Pty Ltd now owns 11,800 shares of the company’s stock worth $54,000 after purchasing an additional 9,000 shares in the last quarter. 87.96% of the stock is currently owned by institutional investors.

About Aveanna Healthcare

(Get Free Report)

Aveanna Healthcare Holdings Inc, a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities.

Featured Articles

Receive News & Ratings for Aveanna Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aveanna Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.